Angehängte Grafik: rcel-avitatherapeutics_gap_sep2019.jpg (verkleinert auf 89%)
: evenue of $5.0 million in the 1st quarter of 2020
Zitat:"....today reported financial results for its fiscal first quarter of 2021, ended September 30, 2020.....First Quarter Highlights..... Reported U.S based RECELL® revenue of $5.0 million in the first quarter of 2021, a 59% increase over the same quarter prior year Total global revenue of $5.1 million in the first quarter of 2021, a 56% increase over the same quarter prior year...... Commercial metrics:.... ? Procedural volumes were 496 in the first quarter of 2021, an increase of 27.2% over the prior quarter....... ? Added 9 new accounts in the first quarter 2021 for a total of 86 accounts.... Enrolled first patient in the pivotal study assessing the use of the RECELL® System to treat stable vitiligo...." ENDE Zitat Quelle:https://www.stockwatch.com/News/...01110&symbol=RCEL®ion=U
: Cash was $65.8 million as of September 30, 2020.
Zitat:"....First Quarter 2021Financial Results.....Revenue was $5.1 million in the first quarter of 2021, compared to $3.3 million for the same quarter last year and $3.9 million for the prior quarter......Gross margin was 82% for the first quarter of 2021, compared with 81% in the same quarter last year.....Operating expenses were $14.9 million for the first quarter of 2021, compared with $8.3 million in the same quarter last year. The increase was............................................. primarily driven by the additional costs of the Company?s status as a dual listed entity on NASDAQ and the ASX, along with commencement of pivotal clinical trials for the treatment of pediatric scald injuries, ....................................soft tissue reconstruction, vitiligo and other research and development activities to further promote the RECELL System............Net loss was $10.2 million for the first quarter of 2021 and net loss per share was $0.48 on a weighted-average basic and diluted share count of 21.5 million............................., compared to $3.6 million and a net loss per share of $0.19 on a weighted-average basic and diluted share count of 18.7 million in the same period of the prior year......" ENDE Zitat Quelle:https://www.stockwatch.com/News/...01110&symbol=RCEL®ion=U Cash was $65.8 million as of September 30, 2020.
: 4cm2 gesunde Haut = 320 cm2 Behandlungsflaeche
Zitat:"...Bei diesem Verfahren wird eine 0,2 bis 0,3 mm dünne 1 cm² bis 4 cm² große Hautschicht (Spalthaut) aus einem gesunden Areal, zum Beispiel hinter dem Ohr, Leiste oder Oberarminnenseite in örtlicher Betäubung entnommen.......Mit einer entnommenen 1 cm² bzw. 4 cm² großen gesunden Hautoberfläche kann eine 80 cm² bzw. 320 cm² große Fläche behandelt werden. Die erste Hautschicht bildet sich innerhalb einer Woche....." ENDE Ziat Quelle:https://plastische-frankfurt.de/eingriff/frau/...irn-und-augenbrauen/
: obal revenue is expected to be $5.1 million
Zitat:"....Preliminary Fiscal Second Quarter Estimates
U.S based RECELL® revenue is expected to be $5.0 million in the second quarter of 2021 ended December 31, 2020, compared to $5.0 million in the previous quarter. U.S based RECELL revenue increased $1.9 million or 62% over the same quarter in the prior year. Total global revenue is expected to be $5.1 million in the second quarter of 2021, compared to $5.1 million in the previous quarter. Total global revenue increased $1.8 million in the current quarter or 57% over the same quarter in the prior year. The Company had cash of approximately $59.8 million, a decrease of $6.0 million or 9% over the $65.8 million held at the end of the previous quarter....."Ende Zitat
sollte dies so bleiben... bislang konnte ich zu einem möglichen delisting nichts finden... wäre dies ggf. eine gute Alternative zu den ADRs... (aber weshalb gibt es Avita Medical und Avita Therapeutics ?)
Zitat: "-.........VITA Medical, Inc. RCEL has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because RCEL is now in overbought territory with an RSI value of 80.34.....what is RSI?... readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.....Other Factors... Over the past one month, investors have witnessed 2 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for RCEL?s has also been on a downward trend over the same time period too, as the estimates have fallen 13% over the last two months..... ..this wasn?t enough,.................... AVITA Medical also has a Zacks Rank #5 (Strong Sell) which puts it into unfortunate company among its peers. So, given all of these factors, i...................nvestors may want to consider exiting this stock now before it falls back to Earth. ..." ENDE Zitat Quelle:https://finance.yahoo.com/news/...rcel-overbought-drop-130101903.html
: RCEL Announce Fiscal II.Q.2021 Financial Result
Zitat:"....announced today it plans to release its fiscal second quarter 2021 financial results after the market closes onNASDAQ onThursday, February 11, 2021. Inconjunction with such release, the Company plans to host a conference call and webcast on February 11th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time(being 8.30am on Friday, February 12, 2021 in Sydney)to discuss its financial results and recent highlights..." ENDE Zitat
n.b. derzeit können Anteile in der ISIN: US05380C1027 (US-Symbol: RCEL) von mir nicht in mein/e Wikifolio gekauft werden, da ausschliesslich Kursnotierungen durch L&S via Handelsplatz, für Käufe in Wikifolios möglich sind. Daher habe ich mich nun doch dazu entschlossen, (siehe #20) für diverse von mir geführte BranchenWikifolio, Anteile in der WKN: A2P8DT - ISIN: AU000000AVH4 - US-Symbol: AVHHL zu erwerben. Ich hoffe das stellt sich im Nachhinein nicht doch als Fehler heraus und die Titel sind auch künftig weiterhin handelbar....
: Cash was $59.8 million as of December 31, 2020.
Zitat:"Second Quarter Highlights..... Reported U.S based RECELL® revenue of $5.0 million in the second quarter of 2021 ended December 31, 2020, a 62% increase over the same quarter in the prior year Reported total global revenue of $5.1 million in the second quarter of 2021 ended December 31, 2020, a 57% increase over the same quarter in the prior year...... Commercial metrics: ° Procedural volumes were 487 in the second quarter of 2021 versus 496 in the prior quarter ended September 30, 2020.... ° Added 7 new accounts in the second quarter 2021 for a total of 93 accounts Enrolled nine patients in the pivotal study assessing the use of the RECELL® System to treat stable vitiligo...Second Quarter 2021 Financial Results Total global revenue was $5.1 million in the second quarter of 2021, compared to $3.3 million for the same quarter last year and flat to the prior quarter ended September 30, 2020.... Gross margin was 84% for the second quarter of 2021, compared with 74% in the same quarter last year, driven largely by the extension of our shelf-life along with lower shipping costs and increased production............Operating expenses were $10.4 million for the second quarter of 2021, compared with $13.4 million in the same quarter last year. ..." ENDE Zitat Quelle:https://www.stockwatch.com/News/...10211&symbol=RCEL®ion=U
: April,2021-Burn Association 53rd AnnualMeeting
Zitat:"...VALENCIA, Calif. and MELBOURNE, Australia, March 30, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced that 15 abstracts highlighting the clinical and cost-savings benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been accepted at the American Burn Association (ABA) 53rd Annual Meeting. The meeting, which will be held virtually April 7-9, 2021, annually brings together more than 2,000 multi-disciplinary burn care professionals from around the world.........................?This year?s ABA meeting features the highest number of presentations on the clinical and health economic benefits of the RECELL System since its U.S. Food and Drug Administration approval in 2018,? said Dr. Mike Perry, AVITA Medical?s Chief Executive Officer. ?The acceptance and adoption of RECELL is reflected in these physician-initiated presentations, representing the collective experience of 20 burn centers......." ENDE Zitat Quelle/n: https://ir.avitamedical.com/news-releases/...-presentation-53r-annual http://ameriburn.org/education/annual-meeting/virtual-content/ https://www.stockwatch.com/News/Item/U-z8206629-U!RCEL-20210330/U/RCEL
: penetration rate 73% of total U.S. burn centers
Zitat:"..Third Quarter Highlights... Reported RECELL® revenue of $8.8 million in the third quarter of 2021, a 126% increase over the same quarter in the prior year...... Commercial metrics: Procedural volumes were 492 in the third quarter of 2021, compared with 408 in the same period last year, and 487 in the prior quarter ended December 31, 2020;...... Added 6 new burn center accounts in the third quarter 2021 for a total of 99 accounts, or a penetration rate of 73% of the 136 total U.S. burn centers;..... Of the approximate 300 total U.S. burn surgeons: 244 U.S. burn surgeons have been trained and certified with RECELL® through the third quarter of 2021, for a penetration rate of 81%; and........ 147 burn surgeons used RECELL® in the third quarter of 2021, for a penetration rate of nearly 50%...." Ende Zitat Quelle:https://www.stockwatch.com/News/Item/U-z8236148-U!RCEL-20210513/U/RCEL